Exploring the therapeutic potential of gamma-glutamyl carboxylase in prostate cancer through integrated multi-omics analysis
Eurasian Journal of Medicine and Oncology · 2026-01-22 · 10 (5) · 025320342
DOI: 10.36922/ejmo025320342 ↗Abstract
Introduction: Prostate cancer (PCa) treatment is often limited by heterogeneous therapeutic responses and the emergence of drug resistance, underscoring the urgent need to identify novel therapeutic targets. Objective: This study aims to identify novel susceptibility genes associated with PCa risk by integrating genomic, transcriptomic, and proteomic data. Methods: We performed a genome-wide summary-data-based Mendelian randomization (SMR) analysis leveraging cis-expression quantitative trait loci from multiple tissues and PCa phenotypes. We then applied Bayesian colocalization to confirm that the observed SMR signals reflected shared causal variants. To characterize gamma-glutamyl carboxylase (GGCX) expression in normal and malignant prostate tissues, we integrated bulk transcriptomic and proteomic data from The Cancer Genome Atlas, Gene Expression Omnibus, the International Cancer Genome Consortium, and the Human Protein Atlas. We further investigated the spatial distribution of GGCX within the tumor microenvironment using spatial transcriptomics and Spearman correlation analyses with key stromal and immune cell markers. Finally, we constructed a GGCX-centered gene set by combining weighted gene co-expression network analysis with a random forest model and performed GO and KEGG enrichment analyses to infer its potential biological functions and pathways. Results: SMR identified 53 candidate genes associated with PCa phenotypes, including GGCX (p 0.95). GGCX expression was higher in PCa tissues than in normal prostate tissues (p
EUVIMED